Clinical Trial Search

Primary: Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12 — 87; 95; 63 Number of patients — p=0.015

Primary: Apnea Hypopnea Index — 42.71; 40.95 Apneas or hypopneas per hour sleep

Primary: Plaque Inflammation — 1.59; 1.63 SUV

Primary: Changes in HIV Risk Taking Behavior - Number of Condomless Sex Acts Per Participant — 7.58; 3.69 number of unprotected sex acts — p=<.001

Primary: Efficacy of Lactulose as a Preparation for Colonoscopy. — 8.2; 7.2; 7.5; 8.4 units on a scale

Primary: The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14. — -4.3; -0.5; -3.7; -2.0 milliseconds (msec)

Primary: Change in Walking Distance During 6-Minute Walk Test — 222 feet

Primary: Number of Participants With Serious Adverse Events (SAEs), All-cause Hospitalizations, and Protocol-defined Wheezing Illness (PDWI) Episodes — 6; 0; 13; 16 participants

Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute

Primary: Volume of Distribution Estimated Pharmacokinetic Parameter — 27.9; NA Liters — p=<0.05

Primary: Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers) — 81.7; 88.8; 7.1 Percent Accuracy — p=0.0029

Primary: Annualized Height Velocity(cm/Year) After 26 Weeks — 10.68; 5.72 cm/year

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0 percentage of participants

Primary: Bone Mineral Density (BMD) of Spine and Hip by Dual-energy X-ray Absorptiometry (DEXA) at Baseline, Month 12, and Month 24 — 1.06; 1.07; 1.06; 0.88 g/cm^2

Primary: Retention Rate After 52 Weeks Maintenance Period — 104; 98 participants